Early Cefiderocol Treatment Improves Outcomes in Critically Ill Patients with Respiratory Infections, New Data Shows

New real-world data presented at IDWeek 2026 by Shionogi & Co., Ltd. indicates that early treatment with Fetroja®/Fetcroja® (cefiderocol) significantly improved clinical outcomes in critically ill U.S. patients with respiratory infections caused by carbapenem-resistant Gram-negative bacteria, compared to salvage therapy. The data also highlighted cefiderocol's sustained potent in vitro activity against *Pseudomonas aeruginosa* in ventilator-associated pneumonia (VAP) isolates. Cefiderocol is approved in the U.S. for complicated urinary tract infections and hospital-acquired/ventilator-associated bacterial pneumonia.